Outcomes of Dogs with Grade 3 Mast Cell Tumors: 43 Cases (1997-2007)

被引：62

作者：

Hume, Carrie Tupper

Kiupel, Matti ^{[2
]}

Rigatti, Lora ^{[3
]}

Shofer, Frances S. ^{[1
]}

Skorupski, Katherine A.

Sorenmo, Karin U.

机构：

[1] Univ Penn, Matthew J Ryan Vet Hosp, Sch Vet Med, Dept Clin Studies, Philadelphia, PA 19104 USA

[2] Michigan State Univ, Diagnost Ctr Populat & Anim Hlth, Dept Pathobiol & Diagnost Invest, E Lansing, MI 48824 USA

[3] Univ Penn, Sch Vet Med, Dept Pathobiol, Philadelphia, PA 19104 USA

来源：

JOURNAL OF THE AMERICAN ANIMAL HOSPITAL ASSOCIATION | 2011年 / 47卷 / 01期

关键词：

C-KIT; CHEMOTHERAPY; VINBLASTINE; SURVIVAL; PREDNISONE; PROGNOSIS; EFFICACY; RECEPTOR; LIGAND;

D O I：

10.5326/JAAHA-MS-5557

中图分类号：

S85 [动物医学（兽医学）];

学科分类号：

0906 ;

摘要：

This study reports the outcomes of dogs with grade 3 mast cell tumors (MCTs). Clinical and histopathological data were available for 43 dogs. Median progression-free survival (PFS) and overall survival (OS) were 133 and 257 days, respectively. Tumor size, lymph node (LN) status, and mitotic index (MI) significantly influenced PFS in univariate analysis. Tumor size and LN status remained significant in the multivariate analysis. Lymph node status, local tumor control, LN treatment, and MI significantly influenced OS in univariate analysis but only LN status remained significant in multivariate analysis. These results confirm that locoregional control improves outcomes in patients with grade 3 MCTs. (J Am Anim Hosp Assoc 2011; 47: 37-44. DOI 10.5326/JAAHA-MS-5557)

引用

页码：37 / 44

页数：8

共 25 条

[1] PROGNOSIS FOLLOWING SURGICAL REMOVAL OF MASTOCYTOMAS IN DOGS [J].